{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:16:59Z","timestamp":1791181019083,"version":"4.1.0"},"reference-count":20,"publisher":"American Diabetes Association","issue":"6","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,6,1]]},"abstract":"<jats:p>OBJECTIVE\u2014To determine if a human fibroblast\u2013derived dermal substitute could promote the healing of diabetic foot ulcers.<\/jats:p>\n               <jats:p>RESEARCH DESIGN AND METHODS\u2014A randomized, controlled, multicenter study was undertaken at 35 centers throughout the U.S. and enrolled 314 patients to evaluate complete wound closure by 12 weeks. Patients were randomized to either the Dermagraft treatment group or control (conventional therapy). Except for the application of Dermagraft, treatment of study ulcers was identical for patients in both groups. All patients received pressure-reducing footwear and were allowed to be ambulatory during the study.<\/jats:p>\n               <jats:p>RESULTS\u2014The results demonstrated that patients with chronic diabetic foot ulcers of &amp;gt;6 weeks duration experienced a significant clinical benefit when treated with Dermagraft versus patients treated with conventional therapy alone. With regard to complete wound closure by week 12, 30.0% (39 of 130) of Dermagraft patients healed compared with 18.3% (21 of 115) of control patients (P = 0.023). The overall incidence of adverse events was similar for both the Dermagraft and control groups, but the Dermagraft group experienced significantly fewer ulcer-related adverse events.<\/jats:p>\n               <jats:p>CONCLUSIONS\u2014The data from this study show that Dermagraft is a safe and effective treatment for chronic diabetic foot ulcers.<\/jats:p>","DOI":"10.2337\/diacare.26.6.1701","type":"journal-article","created":{"date-parts":[[2007,3,5]],"date-time":"2007-03-05T22:51:27Z","timestamp":1173135087000},"page":"1701-1705","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":613,"title":["The Efficacy and Safety of Dermagraft in Improving the Healing of Chronic Diabetic Foot Ulcers"],"prefix":"10.2337","volume":"26","author":[{"given":"William A.","family":"Marston","sequence":"first","affiliation":[{"name":"University of North Carolina School of Medicine, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Hanft","sequence":"additional","affiliation":[{"name":"Foot & Ankle Institute of South Florida, South Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Norwood","sequence":"additional","affiliation":[{"name":"Valley Endocrine, Fresno, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Pollak","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center, San Antonio, Texas; and the Dermagraft Joint Venture, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Dermagraft Diabetic Foot Ulcer Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031218020686000_R1","doi-asserted-by":"crossref","unstructured":"Sanders LJ: Diabetes mellitus: prevention of amputation. J Am Podiatric Assoc\u200884:322\u2013328, 1994","DOI":"10.7547\/87507315-84-7-322"},{"key":"2022031218020686000_R2","doi-asserted-by":"crossref","unstructured":"Levin M: Prevention and treatment of diabetic foot ulcers. J Wound Ostomy Continence Nurs\u200821:129\u2013146, 1998","DOI":"10.1097\/00152192-199805000-00006"},{"key":"2022031218020686000_R3","doi-asserted-by":"crossref","unstructured":"Bloomgarden ZT: American Diabetes Association 60th Scientific Sessions, 2002: the diabetic foot. Diabetes Care\u200824:946\u2013951, 2001","DOI":"10.2337\/diacare.24.5.946"},{"key":"2022031218020686000_R4","doi-asserted-by":"crossref","unstructured":"Ollendorf D, Kotsanos J, Wishner W: Potential economic benefits of lower-extremity amputation prevention strategies in diabetes. Diabetes Care\u200821:1240\u20131245, 1998","DOI":"10.2337\/diacare.21.8.1240"},{"key":"2022031218020686000_R5","doi-asserted-by":"crossref","unstructured":"Loots MA, Lamme EN, Mekkes J, Middlekoop E: Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J Invest Dermatol\u2008111:850\u2013857, 1998","DOI":"10.1046\/j.1523-1747.1998.00381.x"},{"key":"2022031218020686000_R6","doi-asserted-by":"crossref","unstructured":"Lazarus G, Cooper DM, Knighton DR, Margolis DJ, Pecoraro RE, Rodeheaver G, Robson MC: Definitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol\u2008130:489\u2013493, 1994","DOI":"10.1001\/archderm.130.4.489"},{"key":"2022031218020686000_R7","doi-asserted-by":"crossref","unstructured":"Hehenberger K, Heilborn K, Brismar K, Hansson A: Inhibited proliferation of fibroblasts derived from chronic diabetic wounds and normal dermal fibroblasts treated with high glucose is associated with increased formation of L-lactate. Wound Rep Regen\u20086:135\u2013141, 1998","DOI":"10.1046\/j.1524-475X.1998.60207.x"},{"key":"2022031218020686000_R8","doi-asserted-by":"crossref","unstructured":"Falanga VF, Grinnel B, Gilchrist Y, Maddox T, Moshelle A: Experimental approaches to chronic wounds. Wound Rep Reg\u20083:132\u2013140, 1995","DOI":"10.1046\/j.1524-475X.1995.30205.x"},{"key":"2022031218020686000_R9","doi-asserted-by":"crossref","unstructured":"Naughton G, Mansbridge J, Gentzkow G: A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artificial Organs\u200821:1203\u20131210, 1997","DOI":"10.1111\/j.1525-1594.1997.tb00476.x"},{"key":"2022031218020686000_R10","unstructured":"Reiber GE, Boyko EJ, Smith DG: Lower extremity foot ulcers and amputations in diabetics. In Diabetes in America. 2nd ed. Harris MI, Cowie C, Stern MP, Eds. NIH Publications No. 95, 1995, p. 1468"},{"key":"2022031218020686000_R11","unstructured":"Gentzkow GD, Jensen JL, Pollak RA, Kroeker RA, Lerner JM, Iwasaki SD: Improved healing of diabetic foot ulcers after grafting with a living human dermal replacement. Wounds\u200811:77\u201384, 1999"},{"key":"2022031218020686000_R12","doi-asserted-by":"crossref","unstructured":"Hanft JR, Surprenant MS: Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis. J Foot Ankle Surg\u200841:291\u2013299, 2002","DOI":"10.1016\/S1067-2516(02)80047-3"},{"key":"2022031218020686000_R13","doi-asserted-by":"crossref","unstructured":"Steed DL, and the Diabetic Foot Ulcer Study Group: Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic foot ulcers. J Vasc Surg\u200821:71\u201381, 1995","DOI":"10.1016\/S0741-5214(95)70245-8"},{"key":"2022031218020686000_R14","doi-asserted-by":"crossref","unstructured":"Veves A, Falanga V, Armstrong D, Sabolinski M, for the Diabetic Foot Ulcer Group: Graftskin, a human skin equivalent, is effective in the management of non-infected neuropathic diabetic foot ulcers: a prospective randomized multi-center clinical trial. Diabetes Care\u200824:290\u2013295, 2001","DOI":"10.2337\/diacare.24.2.290"},{"key":"2022031218020686000_R15","doi-asserted-by":"crossref","unstructured":"Pinney E, Liu K, Sheeman B, Mansbridge J: Human three-dimensional fibroblasts cultures express angiogenic activity. J Cell Physiol\u2008183:74\u201382, 2000","DOI":"10.1002\/(SICI)1097-4652(200004)183:1<74::AID-JCP9>3.0.CO;2-G"},{"key":"2022031218020686000_R16","unstructured":"Harding KG, Brassard A, Dolynchuck K: Treatment of \u201chard to heal\u201d venous leg ulcers with a human dermal replacement tissue (Dermagraft): a clinical, laboratory evaluation (Abstract). First World Wound Healing Congress, Melbourne, Australia, 2000"},{"key":"2022031218020686000_R17","doi-asserted-by":"crossref","unstructured":"Krejci-Papa NC, Hoang A, Hansbrough JF: Fibroblast sheets enable epithelialization of wounds that do not support keratinocyte migration. Tissue Engin\u20085:555\u2013561, 1999","DOI":"10.1089\/ten.1999.5.555"},{"key":"2022031218020686000_R18","doi-asserted-by":"crossref","unstructured":"Kern A, Liu K, Mansbridge J: Modification of fibroblast interferon-gamma response by dermal fibroblast extracellular matrix. Ann N Y Acad Sci 961: 364\u2013367, 2002","DOI":"10.1111\/j.1749-6632.2002.tb03125.x"},{"key":"2022031218020686000_R19","unstructured":"Browne AC, Vearncombe M, Sibbald RG: High bacterial load in asymptomatic diabetic patients with neurotrophic ulcers retards wound healing after application of Dermagraft. Ostomy Wound Manage\u200847:44\u201349, 2001"},{"key":"2022031218020686000_R20","doi-asserted-by":"crossref","unstructured":"Falanga V: Classifications for wound bed preparation and stimulation of chronic wounds. Wound Rep Regen\u20088:347\u2013352, 2000","DOI":"10.1111\/j.1524-475X.2000.00347.x"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/26\/6\/1701\/591364\/dc0603001701.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/26\/6\/1701\/591364\/dc0603001701.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T18:57:43Z","timestamp":1647111463000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/26\/6\/1701\/26323\/The-Efficacy-and-Safety-of-Dermagraft-in-Improving"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6,1]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diacare.26.6.1701","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,6,1]]}}}